Pipeline

Our pipeline of oncolytic immunotherapies is targeting specific colorectal cancer indications with both high prevalence and significant unmet need.
Product
Indication(s)
Principal Mechanism
Preclinical
Phase I
Phase II
Worldwide Rights
Product Concept: Tumor-specific delivery of potent immune cell recruitment & activating agents avoiding systemic toxicity
NG-350A

pMMR LARC1

FDA Fast-Track Designation
CD40 agonism

Worldwide Rights

Rest-of-World
Greater China
NG-348

mCRC2

Direct T-cell engagement

Worldwide Rights

Product Concept: Tumor-specific delivery of CAR-T targets to enhance the efficacy and/or improve the safety profile of the cell therapy
Undisclosed

Undisclosed

CART-T targeting
& activation
Undisclosed

Product: NG-350A

Preclinical
Phase I
Phase II

Indication: pMMR LARC1 FDA Fast-Track Designation

Principle Mechanism: CD40 agonism

Transgene Payload:

Worldwide Rights:

Rest-of-World
Greater China

Product: NG-348

Preclinical
Phase I
Phase II

Indication: mCRC2

Principle Mechanism: Direct T-cell engagement

Transgene Payload:

Worldwide Rights:

Product: Undisclosed

Preclinical
Phase I
Phase II

Indication: Undisclosed

Principle Mechanism: CART-T targeting
& activation

Transgene Payload:

1. Mismatch repair-proficient locally advanced rectal cancer (pMMR LARC); 2. Metastatic colorectal cancer (mCRC)

T-SIGn® therapeutics have been clinically evaluated as monotherapy and in combination with other immuno-oncology agents, demonstrating a consistent safety & tolerability profile in addition to promising preliminary efficacy.